Home  »  Business   »  ACADIA Pharmaceuticals Inc. (ACAD) and the Battle ...

ACADIA Pharmaceuticals Inc. (ACAD) and the Battle of Fundamentals vs. Technicals

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) went down by -2.68% from its latest closing price compared to the recent 1-year high of $55.05. The company’s stock price has collected -4.20% of loss in the last five trading sessions. Press Release reported on 01/10/22 that Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

Is It Worth Investing in ACADIA Pharmaceuticals Inc. (NASDAQ :ACAD) Right Now?

Plus, the 36-month beta value for ACAD is at 0.61.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


ACAD currently public float of 160.17M and currently shorts hold a 4.13% ratio of that float. Today, the average trading volume of ACAD was 1.64M shares.

ACAD’s Market Performance

ACAD stocks went down by -4.20% for the week, with a monthly drop of -3.32% and a quarterly performance of 24.10%, while its annual performance rate touched -58.47%. The volatility ratio for the week stands at 5.01% while the volatility levels for the past 30 days are set at 6.52% for ACADIA Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -7.19% for ACAD stocks with a simple moving average of 6.52% for the last 200 days.

Analysts’ Opinion of ACAD

Many brokerage firms have already submitted their reports for ACAD stocks, with Citigroup repeating the rating for ACAD by listing it as a “Buy.” The predicted price for ACAD in the upcoming period, according to Citigroup is $30 based on the research report published on January 05th of the current year 2022.

Guggenheim, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $28. The rating they have provided for ACAD stocks is “Neutral” according to the report published on December 21st, 2021.

Guggenheim gave a rating of “Buy” to ACAD, setting the target price at $23 in the report published on November 01st of the previous year.

ACAD Trading at 2.39% from the 50-Day Moving Average

After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.78% of loss for the given period.

Volatility was left at 6.52%, however, over the last 30 days, the volatility rate increased by 5.01%, as shares sank -3.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.84% upper at present.

During the last 5 trading sessions, ACAD fell by -4.20%, which changed the moving average for the period of 200-days by -13.89% in comparison to the 20-day moving average, which settled at $23.81. In addition, ACADIA Pharmaceuticals Inc. saw -5.14% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ACAD starting from DAVIS STEPHEN, who sale 3,718 shares at the price of $23.05 back on Jan 06. After this action, DAVIS STEPHEN now owns 58,716 shares of ACADIA Pharmaceuticals Inc., valued at $85,700 using the latest closing price.

Stankovic Srdjan R., the President of ACADIA Pharmaceuticals Inc., sale 1,937 shares at $23.05 during a trade that took place back on Jan 06, which means that Stankovic Srdjan R. is holding 45,019 shares at $44,648 based on the most recent closing price.

Stock Fundamentals for ACAD

Equity return is now at value -32.70, with -25.70 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Spirit Airlines Inc. (SAVE) a Keeper?

Spirit Airlines Inc. (NYSE:SAVE) went down by -0.32% from its latest closing price compared to the recent 1-year high of $40.77. The company’s stock price

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam